Today's Daily Dose brings you news about the amended immuno-oncology collaboration agreement between AnaptysBio and GlaxoSmithKline, BioSig discontinuing its phase II trial of investigational antiviral Merimepodib in COVID-19, the failure of Catabasis' phase III trial of Edasalonexent in Duchenne muscular dystrophy, and Mirati's promising early data of Adagrasib in lung cancer.
from RTT - Biotech https://ift.tt/34uhQna
via IFTTT
No comments:
Post a Comment